07.30.15
INC Research
2Q Revenues: $227.4 million (+14%)
2Q Earnings: $23.3 million (+53%)
YTD Revenues: $438.9 million (+13%)
YTD Earnings: $48.6 million (earnings were $13.8 million YTD14)
Comments: Backlog grew by 12% year-over-year to $1.7 billion as of June 30, 2015. Service revenue growth during both the quarter and first half was primarily driven by continued strong awards over the last two years, a lower cancellation rate of previously awarded business and a positive revenue mix. In 2015, revenue grew across all therapeutic areas and has been particularly strong in the CNS, Oncology and other complex therapeutic areas.
2Q Revenues: $227.4 million (+14%)
2Q Earnings: $23.3 million (+53%)
YTD Revenues: $438.9 million (+13%)
YTD Earnings: $48.6 million (earnings were $13.8 million YTD14)
Comments: Backlog grew by 12% year-over-year to $1.7 billion as of June 30, 2015. Service revenue growth during both the quarter and first half was primarily driven by continued strong awards over the last two years, a lower cancellation rate of previously awarded business and a positive revenue mix. In 2015, revenue grew across all therapeutic areas and has been particularly strong in the CNS, Oncology and other complex therapeutic areas.